期刊
RADIOTHERAPY AND ONCOLOGY
卷 119, 期 2, 页码 306-311出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2016.03.021
关键词
Nelfinavir; Trial; Pancreatic cancer; Hypoxia; Imaging; Radiosensitisation
资金
- Cancer Research UK
- Kidani Memorial Trust
- Medical Research Council
- NIHR Biomedical Research Oxford
- Cancer Research UK [16466, 19277, 16049] Funding Source: researchfish
- Medical Research Council [MC_PC_12004, MC_PC_12001/2] Funding Source: researchfish
- MRC [MC_PC_12001/2, MC_PC_12004] Funding Source: UKRI
Background and purpose: Nelfinavir can enhance intrinsic radiosensitivity, reduce hypoxia and improve vascularity. We conducted a phase II trial combining nelfinavir with chemoradiotherapy (CRT) for locally advanced inoperable pancreatic cancer (LAPC). Materials and methods: Radiotherapy (50.4 Gy/28 fractions; boost to 59.4 Gy/33 fractions) was administered with weekly gemcitabine and cisplatin. Nelfinavir started 3-10 days before and was continued during CRT. The primary end-point was 1-year overall survival (OS). Secondary end-points included histological downstaging, radiological response, 1-year progression free survival (PFS), overall survival (OS) and treatment toxicity. An imaging sub-study (n = 6) evaluated hypoxia (F-18-Fluoromisonidazole-PET) and perfusion (perfusion CT) during induction nelfinavir. Results: The study closed after recruiting 23 patients, due to non-availability of Nelfinavir in Europe. The 1-year OS was 73.4% (90% CI: 54.5-85.5%) and median OS was 17.4 months (90% CI: 12.8-18.8). The 1 year PFS was 21.8% (90% CI: 8.9-38.3%) and median PFS was 5.5 months (90% CI: 4.1-8.3). All patients experienced Grade 3/4 toxicity, but many were asymptomatic laboratory abnormalities. Four of 6 patients on the imaging sub-study demonstrated reduced hypoxia and increased perfusion post-nelfinavir. Conclusions: CRT combined with nelfinavir showed acceptable toxicity and promising survival in pancreatic cancer. (C) 2016 The Authors. Published by Elsevier Ireland Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据